Articles from Basilea Pharmaceutica International Ltd, Allschwil

Strong Cresemba® (isavuconazole) sales in Europe trigger USD 37.5 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · November 3, 2026

Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · October 27, 2026

Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Allschwil, Switzerland, October 20, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · October 20, 2026

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

Allschwil, Switzerland, September 14, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · September 14, 2026

Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · August 18, 2026

Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · August 5, 2026

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · July 29, 2026

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · May 28, 2026

Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting

Allschwil, Switzerland, April 15, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · April 15, 2026

Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · April 9, 2026

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Allschwil, Switzerland, March 23, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · March 23, 2026

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 25, 2026

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

Ad hoc announcement pursuant to Art. 53 LR

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 17, 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, February 09, 2026

By Basilea Pharmaceutica International Ltd, Allschwil · Via GlobeNewswire · February 9, 2026